SEARCH

SEARCH BY CITATION

References

  • 1
    Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928936.
  • 2
    Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218227.
  • 3
    Paya CV, Razonable RR. Cytomegalovirus infection after organ transplantation. In: BowdenRA, LjungmanP, PayaCV, eds. Transplant Infections, 2nd Ed. Philadelphia : Lippincott, Williams and Wilkins, 2003: 298232.
  • 4
    Rubin RH. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: The end of the ‘silo hypothesis’. Curr Opin Infect Dis 2007; 20: 399407.
  • 5
    Kranz B, Vester U, Wingen A-M et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008; 12: 474478.
  • 6
    Hjelmesaeth J, Muller F, Jenssen T, Rollag H, Sagedal S, Hartmann A. Is there a link between cytomegalovirus infection and new-onset post transplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage. Nephrol Dial Transplant 2005; 20: 23112315.
  • 7
    Cytomegalovirus. Am J Transplant 2004; 4(Suppl 10): 5158.
  • 8
    Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 21052115.
  • 9
    Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870880.
  • 10
    Lowance D, Neumayer HH, Legendre CM et al. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 14621470.
  • 11
    Limaye AP, Bakthavatsalam R, Kim HW et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78: 13901396.
  • 12
    Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 11061111.
  • 13
    Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4: 16351642.
  • 14
    Valentine VG, Weill D, Lombard GA et al. Ganciclovir for cytomegalovirus: A call for indefinite prophylaxis. Am J Transplant 2007; 7 (S2): 505.
  • 15
    Valentine VG, Weill D, Gupta MR et al. Ganciclovir for cytomegalovirus: A call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008; 27: 875881.
  • 16
    Schnitzler MA, Lowell JA, Hmiel SP et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: The importance of HLA-DR matching. J Am Soc Nephrol 2003;14:780785.
  • 17
    Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262274.
  • 18
    Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645649.
  • 19
    Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611620.
  • 20
    Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006;6:21342143.
  • 21
    Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol 2006;16:281287.
  • 22
    Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975983.
  • 23
    Solidoro P, Libertucci D, Delsedime L et al. Combined cytomegalovirus prophylaxis in lung transplantation: Effects on acute rejection, lymphocytic bronchitis/bronchiolitis, and herpes virus infections. Transplant Proc 2008; 40: 20132014.
  • 24
    Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009; 20: 24492458.
  • 25
    Pouteil-Noble C, Ecochard R, Betuel H, Dubernard JM, Aymard M, Touraine JL. HLA B and DR mismatching, a risk factor for cytomegalovirus infection after renal transplantation. Clin Transplantation 1993; 7: 467474.